RNAi: a potential new class of therapeutic for human genetic disease.
about
Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of diseaseCirculating microRNAs as biomarkers, therapeutic targets, and signaling moleculesReduced stability and intracellular transport of dsRNA contribute to poor RNAi response in lepidopteran insectsRNA interference-based nanosystems for inflammatory bowel disease therapyRapid Exchange Between Free and Bound States in RNA-Dendrimer Polyplexes: Implications on the Mechanism of Delivery and ReleaseRNA interference-based therapeutics for inherited long QT syndromeLentivirus-mediated RNA interference of tripartite motif 68 inhibits the proliferation of colorectal cancer cell lines SW1116 and HCT116 in vitroAutosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics.Vasopressin V2R-targeting peptide carrier mediates siRNA delivery into collecting duct cellsAdvances with RNA interference in Alzheimer's disease research.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse modelIncreased HOX C13 expression in metastatic melanoma progression.Prion-like propagation of protein aggregation and related therapeutic strategies.Hyperexpression of HOXC13, located in the 12q13 chromosomal region, in well‑differentiated and dedifferentiated human liposarcomas.The Sound of Silence: RNAi in Poly (ADP-Ribose) ResearchQuantum Dots-siRNA Nanoplexes for Gene Silencing in Central Nervous System Tumor Cells.Using non-coding small RNAs to develop therapies for Huntington's disease.Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.HOX Gene Aberrant Expression in Skin Melanoma: A Review.siRNA therapeutics in the treatment of diseases.Hereditary ataxias: overview.Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors.The aggregation of mutant p53 produces prion-like properties in cancer.Characterization of nucleic acids by tandem mass spectrometry - The second decade (2004-2013): From DNA to RNA and modified sequences.Comprehensive overview and assessment of computational prediction of microRNA targets in animals.Induced pluripotent stem cells and their use in cardiac and neural regenerative medicineApplication of biodegradable dendrigraft poly-l-lysine to a small interfering RNA delivery system.A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences.Lentivirus-mediated TPD52L2 depletion inhibits the proliferation of liver cancer cells in vitro.Protein aggregation, misfolding and consequential human neurodegenerative diseases.Biodegradable nanocapsules as siRNA carriers for mutant K-Ras gene silencing of human pancreatic carcinoma cells.Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.ASPsiRNA: A Resource of ASP-siRNAs Having Therapeutic Potential for Human Genetic Disorders and Algorithm for Prediction of Their Inhibitory Efficacy.RNA interference: A futuristic tool and its therapeutic applications.Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.Advances in the Application and Impact of MicroRNAs as Therapies for Skin DiseaseReductive nanocomplex encapsulation of cRGD-siRNA conjugates for enhanced targeting to cancer cells.Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases.A novel measurement of allele discrimination for assessment of allele-specific silencing by RNA interference.
P2860
Q26764958-640818B8-F86E-454F-9631-E96E55D2438DQ26997097-37E18B31-6AEA-42E9-82AA-8B461B682C94Q27311319-34F73685-2EB7-4DA2-8A2D-E4C7DB873937Q28071518-F8DC6062-DB54-4BD5-96B0-D7FACCB52BF2Q28821628-721D7785-4854-4CEC-8D22-FEFF4D06A57BQ33166507-D4C16CC6-6D8F-448A-A58C-0B3D2691E306Q33598835-3611D861-434F-49D0-AAF9-57630435B8F4Q34323333-601F159C-6C9F-4E08-A7A3-394041880A7EQ34326732-5439F4CD-3C77-4A77-A53F-3CE084E46746Q34330911-33588D5E-114F-4CE0-8F89-552688370AAFQ34622662-48D73893-70DF-4CA1-9F0B-413FF8DCEA4BQ35546692-F32BFE21-CECF-4AE1-8EBE-42242F8577B6Q36338556-69028E19-B7D9-44D0-8AEA-F99A15FA264EQ36983208-6628D0AD-3228-4674-89C6-75B7FACB948EQ37341266-B72B0673-39F0-4E48-BCEF-0239196D22E3Q37508170-2EA6093C-AC14-4AEA-BF29-555BADD7BBB4Q37736085-86002144-92D8-4ADE-8A0D-BC17C911B402Q37967034-E0A17E82-68D5-4C87-A61C-3BF2A874BE9DQ38037048-BF583685-F3C6-44AC-B4BD-1896FD3ECD11Q38054730-9DC55DB5-BA10-43EF-9549-0D4280BE777CQ38074462-C945D7B3-EB15-4D70-B56B-48BD322BA3D9Q38094029-5AC2F354-8084-45DB-8DB9-B1F845F07C24Q38148788-1C20C6C2-B55E-418B-BCFD-8FB21FE262F8Q38186535-057AA620-1EBA-48E0-A5B3-28A5B95306E1Q38257494-56411FB4-A05E-4CEF-88A7-407FF03935D0Q38282622-7F425D3B-EC3E-473C-915F-FB84E0FF9638Q38358569-8044FB37-45FE-4155-A0C9-00139143D057Q38774763-EF42B07C-E7A7-4806-8916-03BB0ABF3379Q38815929-E6A6193B-DE6B-478A-BFBE-21590FA8788BQ38880242-591AC049-46C4-442C-9F72-3432398F1368Q39097864-E24A7DB3-EF8D-44D0-9187-47BF5FCD3337Q39191239-9D6F8623-5BA4-4EE3-97F4-9E87DB5BD9BBQ39795092-A39D20EF-CCC1-4426-AF8B-94BC7AC8CE71Q41385002-E825AE9A-1E4F-4589-94C4-A39EAF70F5ECQ41848470-2ACC2E00-7222-4540-B5C3-B07BBBAC37D3Q41994816-585472D3-784C-49CC-9393-00E04895E194Q42362861-767B2165-3D97-45F1-BD7F-4073FF511737Q42373829-36E61F7C-9DB7-4B87-95F0-E1253E2D1BBBQ43082851-FDDDD7E4-F75E-42C8-8217-36C0FFDB0E08Q43890141-881AF69C-18B0-4B41-932B-19358704A16D
P2860
RNAi: a potential new class of therapeutic for human genetic disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RNAi: a potential new class of therapeutic for human genetic disease.
@en
RNAi: a potential new class of therapeutic for human genetic disease.
@nl
type
label
RNAi: a potential new class of therapeutic for human genetic disease.
@en
RNAi: a potential new class of therapeutic for human genetic disease.
@nl
prefLabel
RNAi: a potential new class of therapeutic for human genetic disease.
@en
RNAi: a potential new class of therapeutic for human genetic disease.
@nl
P2860
P1433
P1476
RNAi: a potential new class of therapeutic for human genetic disease.
@en
P2093
Attila A Seyhan
P2860
P2888
P304
P356
10.1007/S00439-011-0995-8
P577
2011-05-03T00:00:00Z